Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real-World Study. (PubMed, Int J Urol) - Sep 15, 2026 - "Recurrence after adjuvant nivolumab occurred in 28% of patients in real-world practice. Post-recurrence management was heterogeneous, and EV-based therapy was frequently used in this setting. These findings provide hypothesis-generating real-world evidence on treatment sequencing after adjuvant nivolumab and require validation in larger cohorts with longer follow-up."
Journal • Real-world evidence • Retrospective data • Oncology • Solid Tumor • Urothelial Cancer
|
|
Chikara Ohyama; Hayato Yamamoto; Izuki Ogawa; Jotaro Mikami; Kazuyuki Numakura; Masanao Shinohara; Naoki Fujita; Noriyuki Abe; Satoshi Sato; Shin Kobayashi; Shingo Hatakeyama; Shintaro Narita; Shunsuke Tazawa; Takuma Narita; Teppei Okamoto; Tomonori Habuchi; Yohei Kawashima; Yuya Sekine
|